Contact Dermatitis in 305 Canadian Aircraft Workers
Doctor’s Notes · Life in Motion · Evidence Review
Editorial disclosure: The featured scene is an AI-created illustration of a fictional work, home or research setting. It is not a patient, diagnosis, before-and-after image or Dr. Arsy #003 treatment result.
The question behind this paper
This review looks at aircraft assembly, composites and epoxy exposure. The aim is to preserve the study’s actual population, denominator, design and timepoint so a useful signal does not become a universal claim.
Study snapshot
| Study element | Reported detail |
|---|---|
| Population | 305 aerospace workers referred to a Canadian contact-dermatitis clinic |
| Design | Retrospective 1990–2015 occupational referral-clinic series |
| Timepoint | Twenty-five years of clinical records |
| Key result | Allergic contact dermatitis was diagnosed in 152 and irritant dermatitis in 96. Of 152 allergic cases, 124 reacted to epoxy-based workplace products, but only 48 reacted to commercially available epoxy allergens. |
How to interpret the result
Testing only a standard tray would have missed many reactions in this referral series. That supports specialist use of verified workplace materials, not unsupervised testing or assumptions based on job title.
Important limitation: Workers were referred because of suspected disease, workplace formulations changed over time, and clinic proportions are not prevalence for the aircraft workforce.
Questionnaires, examinations, sensors, patch tests and administrative records answer different questions. A screening or monitoring result can guide the next step, but it does not diagnose the cause of one person’s rash. An association can identify a pattern worth investigating without proving that a single task, material or personal factor caused every event.
Questions a worker, family or clinician can ask next
- What exactly was measured: reported symptoms, visible signs, allergy, work loss or quality of life?
- Which denominator applies to the quoted percentage: everyone invited, respondents, symptomatic people, examined participants or a selectively tested subgroup?
- Did the study compare groups or follow change over time, and what factors could still explain the difference?
- Would clinician examination, occupational-health review or clinician-directed testing change the practical plan?
- What requires prompt medical evaluation, including rapidly spreading redness, drainage, fever, severe pain, breathing symptoms or major loss of function?
Primary and authoritative sources
- Primary medical research record: PubMed PMID 29762207
- Authoritative guidance relevant to this topic
- American Academy of Dermatology: eczema skin-care guidance
PubMed indexing is not NIH endorsement of a study’s interpretation, this article or any product.
Where a cosmetic moisturizer fits
Dr. Arsy #003 is a cosmetic moisturizer for hydration, moisture-barrier support and dry-skin comfort. This study did not test #003, and outside research does not become a product result. #003 is not an eczema medicine and this article makes no treatment, cure, prevention, pediatric-safety or 24-hour claim.
Bottom line
The responsible conclusion is narrow: keep the population, denominator, comparator, timepoint and limitations attached, then use the evidence to ask better clinical and exposure-control questions rather than promise a universal result.